RE: Pfizer Vaccine out of reach for 2/3rds of world population..20 Nov 2020 17:49
Investo - that was the best point from RM's presentation earlier this week. A very good insight into SNG's medium term strategy.
I spent many days wondering why are we so tight on our trial participants criteria, which seemed counter-intuitive, as relaxing the entry requirements would have filled the places a lot faster. It was only after the presentation when I joined the dots - RM seems to know we can't produce millions of doses, seems to be very confident in the product (throwing it at the most challenging trial subjects) and is looking for premium prices for a premium treatment.
Strap on and enjoy the ride!